Tecan streamlines proteomics workflows with innovative automation and purification columns

Männedorf, Switzerland, February 5, 2024 – Tecan is pleased to announce further expansion of its leading portfolio for specialist applications with the upcoming launch of Resolvex® i300 and its antibody purification columns, AffinEx™ Protein A Capture. The products deliver new levels of efficiency and precision to proteomics workflows, including biomarker discovery, drug development and personalized medicine.

Proteomics laboratories have long struggled with tedious sample preparation, as well as the need to process large numbers of samples quickly and efficiently while minimizing the risk of cross-contamination.

The Resolvex i300, scheduled for launch in H1 2024, is a positive pressure module for solid phase extraction (SPE) and filtration, specifically designed to address all these challenges. Integrated into the Fluent® Automation Workstation, it enables the automation of every step of the sample purification process, including clean-up, evaporation and resuspension. This ensures the integrity and consistency of each sample while the instrument’s unique droplet-protection feature reduces the risk of cross-contamination during labware handling. Designed for use in various fields – including proteomics, genomics and analytical chemistry – the Resolvex i300 can easily be changed between 24- and 96-well labware formats and is particularly useful for liquid chromatography-mass spectrometry (LC-MS)-based applications.

Another exciting addition to Tecan’s portfolio for proteomics is the AffinEx™ Protein A Capture column. This novel antibody purification sorbent is stable, wet or dry, at room temperature, which significantly extends its shelf life and also reduces shipping costs. Available in a Narrow Bore Extraction™ (NBE™) format, AffinEx columns are ideally suited for use with the Resolvex i300, though they can be used with other automation platforms. The columns are specifically tailored to the biopharma industry and promise unparalleled efficiency for the isolation and purification of monoclonal antibodies.

Luca Valeggia, Senior Vice President of Lab Automation at Tecan, said: “Tecan has established a strong reputation in automating proteomics workflows. Resolvex i300 and AffinEx Protein A Capture are exciting additions to our portfolio, enabling us to address a broad range of customer needs, from low- to high-throughput, in both research and clinical settings. As demand for this challenging application grows, we are committed to continuous innovation that supports our customers in their efforts to understand the mechanisms of disease and develop reliable diagnostics and treatments for patients.”

To learn more about Tecan’s Resolvex i300, visit www.tecan.com/proteomics-automation and https://www.tecan.com/affinex-protein-a-capture

For further information

Tecan Group
Benjamin Peltier 
Senior Manager Media and Content
benjamin.peltier@tecan.com
Tel. +41 (0) 44 922 88 88

About Tecan

Tecan (www.tecan.com) improves people’s lives and health by empowering customers to scale healthcare innovation globally from life science to the clinic. Tecan is a pioneer and global leader in laboratory automation. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments, components and medical devices that are then distributed by partner companies. Founded in Switzerland in 1980, the company has around 3,500 employees, with manufacturing, research and development sites in Europe, North America and Asia, and maintains a sales and service network in over 70 countries. In 2022, Tecan generated sales of CHF 1,144 million (USD 1,192 million; EUR 1,144 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).